venBio Partners

Latest statistics and disclosures from venBio Partners's latest quarterly 13F-HR filing:

  • Top 5 stock holdings are PHVS, ALMS, HRMY, ALXO, LYEL, and represent 98.71% of venBio Partners's stock portfolio.
  • Reduced shares in these 2 stocks: LYEL, ARTV.
  • venBio Partners was a net seller of stock by $-6.3M.
  • venBio Partners has $216M in assets under management (AUM), dropping by 22.60%.
  • Central Index Key (CIK): 0001776382

Tip: Access up to 7 years of quarterly data

Positions held by venBio Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Portfolio Holdings for venBio Partners

venBio Partners holds 6 positions in its portfolio as reported in the December 2025 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Pharvaris N V (PHVS) 59.5 $129M 4.6M 27.75
 View chart
Alumis (ALMS) 20.8 $45M 4.6M 9.76
 View chart
Harmony Biosciences Hldgs In (HRMY) 8.5 $18M 489k 37.42
 View chart
Alx Oncology Hldgs (ALXO) 5.1 $11M 9.7M 1.13
 View chart
Lyell Immunopharma Com New (LYEL) 4.8 $10M -28% 338k 30.78
 View chart
Artiva Biotherapeutics (ARTV) 1.3 $2.8M -43% 649k 4.29
 View chart

Past Filings by venBio Partners

SEC 13F filings are viewable for venBio Partners going back to 2019

View all past filings